Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Prospective, Randomized, Controlled Platform Trial Assessing Clinical Utility of Cellular, Acellular and Matrix-like Products (CAMPs) and Standard of Care vs SOC Alone in Hard-to-Heal Diabetic Foot and Venous Leg Ulcers.

NCT06453187 is registered in ClinicalTrials.gov with Integra LifeSciences Corporation as lead sponsor.

NCT NCT06453187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06453187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Prospective, Randomized, Controlled Platform Trial Assessing Clinical Utility of Cellular, Acellular and Matrix-like Products (CAMPs) and Standard of Care vs SOC Alone in Hard-to-Heal Diabetic Foot and Venous Leg Ulcers.
Lead sponsor
Integra LifeSciences Corporation
Phase
Not applicable
Overall status
Enrolling by invitation
Start date
November 18, 2024
Completion date
March 31, 2027
Enrollment
350 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic foot ulcer, venous leg ulcer